Literature DB >> 11115352

Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves.

M Sakon1, K Umeshita, H Nagano, H Eguchi, S Kishimoto, A Miyamoto, S Ohshima, K Dono, S Nakamori, M Gotoh, M Monden.   

Abstract

HYPOTHESIS: The clinical significance of hepatectomy for hepatocellular carcinoma (HCC) is still controversial because of frequent intrahepatic recurrence, which results from either recurrence due to residual intrahepatic metastasis (Rim) or recurrence due to metachronous, multicentric liver carcinogenesis (Rmc).
DESIGN: Retrospective review. Disease-free survival curves were obtained by the Kaplan-Meier method and the rates of Rim and Rmc were analyzed using 2 regression lines, based on the evidence that Rmc occurs at a constant rate throughout follow-up, whereas Rim occurs only in the early postoperative period.
SETTING: University hospital. PATIENTS: From 1980 to 1996, 241 patients with HCC who underwent curative hepatic resection. MAIN OUTCOME MEASURE: Intrahepatic recurrence.
RESULTS: Disease-free survival curves for all patients in the early (within 2 years) and late (4 years after surgery) follow-up were approximated by 2 regression lines, which represent both Rim and Rmc (Y(1) = -3.4X + 48) and only Rmc (Y(2) = -23.1X + 98). Using this approximation, the annual incidence of Rim within 2 years (a(1)-a(2)) was calculated as 19.7% and that of Rmc (a(2)) was 3.4%. The ratio of Rim in tumor recurrence (b(1)-b(2)) was 50%, and that of Rmc (b(1)) was 48%. The ratios of Rmc in patients with stages I and II HCC were 60% and 64%, respectively. In contrast, the values could not be calculated in patients with stages III and IVA because all but 2 patients showed recurrence within 4 years after surgery.
CONCLUSION: Tumor recurrence is estimated to result from metachronous liver carcinogenesis in 48% of hepatectomized patients with HCC.

Entities:  

Mesh:

Year:  2000        PMID: 11115352     DOI: 10.1001/archsurg.135.12.1456

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  35 in total

1.  Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease.

Authors:  Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Pavel Vladimirovich Korita; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

2.  Equivalent outcomes after anatomical and non-anatomical resection of small hepatocellular carcinoma in patients with preserved liver function.

Authors:  Yoshito Tomimaru; Hidetoshi Eguchi; Shigeru Marubashi; Hiroshi Wada; Shogo Kobayashi; Masahiro Tanemura; Koji Umeshita; Yuichiro Doki; Masaki Mori; Hiroaki Nagano
Journal:  Dig Dis Sci       Date:  2012-03-11       Impact factor: 3.199

3.  The influence of high serum testosterone levels on the long-term prognosis in male patients undergoing hepatectomy for early stage hepatocellular carcinoma without vascular invasion.

Authors:  Min-Che Lin; Cheng-Chung Wu; Shao-Bin Cheng; Tse-Jia Liu; Fang-Ku P'eng
Journal:  World J Surg       Date:  2007-07       Impact factor: 3.352

4.  Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma.

Authors:  Li Qiang; Li Huikai; Kelly Butt; P Peter Wang; Xishan Hao
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

5.  The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma.

Authors:  Shogo Kobayashi; Akira Tomokuni; Hidenori Takahashi; Hirofumi Akita; Keijiro Sugimura; Norikatsu Miyoshi; Jeong Ho Moon; Masayoshi Yasui; Takeshi Omori; Masayuki Ohue; Yoshiyuki Fujiwara; Masahiko Yano; Masato Sakon
Journal:  Gastrointest Tumors       Date:  2017-02-08

6.  Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation.

Authors:  Aiman Obed; Alexander Beham; Kerstin Püllmann; Heinz Becker; Hans J Schlitt; Thomas Lorf
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

7.  Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood.

Authors:  Osakuni Morimoto; Hiroaki Nagano; Atsushi Miyamoto; Yoshiyuki Fujiwara; Motoi Kondo; Tameyoshi Yamamoto; Hideo Ota; Masato Nakamura; Hiroshi Wada; Bazarragchaa Damdinsuren; Shigeru Marubashi; Keizo Dono; Koji Umeshita; Shoji Nakamori; Masato Sakon; Morito Monden
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

8.  Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion.

Authors:  Hidetoshi Nitta; Toru Beppu; Katsunori Imai; Hiromitsu Hayashi; Akira Chikamoto; Hideo Baba
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

9.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

10.  miR-615-3p expression level in bone marrow is associated with tumor recurrence in hepatocellular carcinoma.

Authors:  Ryota Mukai; Yoshito Tomimaru; Hiroaki Nagano; Hidetoshi Eguchi; Koshi Mimori; Akira Tomokuni; Tadafumi Asaoka; Hiroshi Wada; Koichi Kawamoto; Shigeru Marubashi; Yuichiro Doki; Masaki Mori
Journal:  Mol Clin Oncol       Date:  2015-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.